Connor Clark & Lunn Investment Management Ltd. Cuts Stake in Oramed Pharmaceuticals Inc. $ORMP

Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 18.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,136 shares of the biotechnology company’s stock after selling 19,926 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.21% of Oramed Pharmaceuticals worth $186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. N.E.W. Advisory Services LLC increased its stake in shares of Oramed Pharmaceuticals by 52.9% during the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 6,540 shares in the last quarter. BML Capital Management LLC increased its stake in shares of Oramed Pharmaceuticals by 14.3% during the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company’s stock worth $6,464,000 after purchasing an additional 376,841 shares in the last quarter. Peapod Lane Capital LLC increased its stake in shares of Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company’s stock worth $540,000 after purchasing an additional 24,985 shares in the last quarter. Boothbay Fund Management LLC boosted its position in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after acquiring an additional 16,857 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $2.07 on Thursday. The firm has a market capitalization of $84.87 million, a price-to-earnings ratio of -5.91 and a beta of 1.60. The company’s 50-day moving average is $2.14 and its two-hundred day moving average is $2.21. Oramed Pharmaceuticals Inc. has a 1-year low of $1.82 and a 1-year high of $3.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, equities analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 17th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.